27574-80-7

Usage

Chemical structure

1,1'-(dodecane-1,12-diyl)bis-1H-pyrrole-2,5-dione consists of two pyrrole-2,5-dione rings connected by a dodecane chain.

Building block

It is commonly used as a building block in the synthesis of organic compounds.

Field of application

It is specifically used in the field of organic electronics and materials science.

Potential applications

It has potential applications in the development of organic semiconductors, photovoltaic devices, and organic light-emitting diodes.

Unique structure

Its unique structure and properties make it a promising candidate for the design and development of novel materials.

Technological applications

It is used for various technological applications due to its promising properties.

Upstream product

• 55750-48-6 N-methoxycarbonylmaleimide 
• 2783-17-7 1,12-Diaminododecane 

Downstream Products

• 1373828-66-0 C₇₆H₆₄N₂O₈ 

Relevant academic research and scientific papers

NOVEL TETRAGALNAC AND PEPTIDE CONTAINING CONJUGATES AND METHODS FOR DELIVERY OF OLIGONUCLEOTIDES

Disclosed herein is a modular composition comprising 1) an oligonucleotide; 2) one or more tetraGalNAc ligands of Formula (I), which may be the same or different; optionally, 3) one or more linkers, which may be the same or different; 4) one or more peptides independently selected from Table 3, which may be the same or different; and optionally, 5) one or more targeting ligands, solubilizing agents, pharmacokinetics enhancing agents, lipids, and/or masking agents.

A New Class of Bradykinin Antagonists: Synthesis and in Vitro Activity of Bissuccinimidoalkane Peptide Dimers

A systematic study on the dimerization of the bradykinin (BK) antagonist D-Arg0-Arg1-Pro2-Hyp3-Gly4-Phe5-Ser6-D-Phe7-Leu8-Arg9 has been performed.The first part of this study involved compounds wherein dimerization was carried out by sequentially replacing each amino acid with cysteine and cross-linking with bismaleimidohexane.The second part of this study utilized a series of bissuccinimidoalkane dimers wherein the intervening methylene chain was varied systematically from n = 2 to n = 12 while the point of dimerization was held constant at position 6.The biological activities of these dimers were then evaluated on BK-induced smooth muscle contraction in two different isolated tissue preparations: guinea pig ileum (GPI) and rat uterus (RU).Several of the dimeric BK antagonists displayed remarkable activites and long durations of action.In addition, dimerization at position 4, 7, 8, or 9 produced dimeric analogues with markedly reduced potency.Rank order of antagonist potency as a function of dimerization position is as follows: rat uterus, 6 > 5 > 0 > 2 > 1 >3 >> 4, 7, 8, 9; guinea pig ileum, 6 > 5 > 3 > 2 > 1 > 0 >> 4, 7, 8, 9.Evaluation of the linker length as represented by the number of methylene units indicated an optimal distance between the two monomeric peptides of six to eight methylene moieties.These studies also revealed that the carbon-chain length significantly affected the duration of action in vitro and resulted in partial agonism effects when n > 8.The optimum activity in vitro was achieved with dimerization at position 6 and n = 6 (designated herein as compound 25; alternatively, CP-0127).Similar effects in potency were also seen when the monomeric antagonist D-Arg0-Arg1-Pro2-Hyp3-Gly4-Phe5-Ser6-D-Phe7-Phe8-Arg9 (NPC-567) was dimerized using similar chemistry.These results suggest that the development of BK antagonists of significant therapeutic potential may be possible using a dimerization strategy that can overcome the heretofore limiting problems of potency and in vivo duration of action found with many of the BK antagonists in the literature.